Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy Against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?"

Authors

L Cheng
B Nelson
M Mehta
Qiuhu Shi, New York Medical CollegeFollow
A Gomez-Simmonds
A Uhlemann

DOI

10.1128/AAC.01163-17

Journal Title

Antimicrobial Agents and Chemotherapy

First Page

e01163-17

Document Type

Response or Comment

Publication Date

9-1-2017

Department

Epidemiology and Community Health

Keywords

AmpC beta-lactamases; bacteremia; piperacillin-tazobactam

Disciplines

Medicine and Health Sciences

Recommended Citation

Cheng, L., Nelson, B., Mehta, M., Shi, Q., Gomez-Simmonds, A., & Uhlemann, A. (2017). Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy Against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?". Antimicrobial Agents and Chemotherapy, 61 (9), e01163-17. https://doi.org/10.1128/AAC.01163-17